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Poster Session I 99Significance: High-dose chemotherapy with autologous stem
cell transplantation (HDC-AuSCT) has become an established pro-
cedure for treatment of multiple myeloma (MM). During HDC-
AuSCT, patients develop a symptom burden that substantially
interferes with daily activities. Theoretical Framework: Symptom
burden is the combined impact of all symptoms on one’s ability to
function as one did before onset of disease and therapy. Problem
and Purpose: Minimizing the symptom burden of HDC-AuSCT
may allow more patients the chance to receive its demonstrated ben-
efits. The purpose of this research was to explore the ability of larger
numbers of CD341 cells to decrease symptom severity during
HDC-AuSCT in patients with MM. Methods: This was a retro-
spective analysis of 17 patients with MM who completed the M.
D. Anderson Symptom Inventory (MDASI) (0–10 measurement
scale) at 6 time points from baseline to 30 days post-HDC-AuSCT.
Four patients received high doses of stem cells (9.5–15  106
CD341 cells/kg) and 13 received standard doses (4–6  106
CD341 cells/kg). Area under the curve (AUC) methodology was
used to describe the severity of the 5 most severe symptoms (fatigue,
lack of appetite, difficulty sleeping, nausea, and pain) that these pa-
tients experienced during the peritransplantation period. Results:
Means and standard deviations of symptom severity measures are
in Table 1. The mean symptom severity of the 2 groups showed
no difference at baseline. The difference in mean daily AUC be-
tween the 2 groups from cell infusion to 30 days post-HDC-AuSCT
approached significance and, more importantly, showed a large ef-
fect size of 1.2 times the common group standard deviation. The
mean symptom severity of the 5 most severe symptoms was signif-
icantly lower at nadir for the group receiving the high cell dose. Im-
plications: The mean symptom severity for the 2 groups began to
diverge sharply after cell infusion. The severity for patients receiv-
ing the larger cell dose declined immediately, whereas the severity
for patients receiving the standard cell dose rose further before de-
clining. The use of larger cell doses to decrease symptoms warrants
prospective testing in a randomized controlled trial. The mecha-
nism behind the ability of larger doses of stem cells to ameliorate
symptom severity is unclear. The known relationship between
symptom development and severity and inflammatory cytokines
(e.g., IL-6) suggests a possible cytokine-based mechanism, which
also should be explored.
Table 1. Symptom Severity during Autologous Stem Cell
Transplantation for Multiple Myeloma
Larger Cell Standard
Dose Cell DoseMeasure Mean SD Mean SD
P Value
(2-Tailed)Severity at baseline
of 5 most severe
symptoms1.35 1.06 1.86 1.71 0.49Severity at nadir
of 5 most severe
symptoms2.55 1.68 6.06 2.26 \0.012Daily AUC of 5 most
severe symptoms63.55 42.02 122.95 51.24 0.053SD 5 standard deviation.268
UPDATE ON FUNGAL INFECTIONS IN PEDIATRIC BONE MARROW
TRANSPLANT PATIENTS AT THE MATTEL CHILDREN’S HOSPITAL AT
UCLA FROM 1991–2006
Simms-Waldrip, T.R., Rosen, G.P., Kempert, P.H., Nielsen, K.,
Moore, T.B. DavidGeffen School ofMedicine at UCLA, Los Angeles, CA.
Objectives:To identify changes in fungal organisms and charac-
teristics of their infections over time in pediatric bone marrow
transplant (BMT) patients. Identify differences in fungal species
causing infections in different BMT patients. Methods: We per-
formed a retrospective cohort study of all 324 patients on the pedi-atric hematology and oncology service at UCLA between 1991 and
2006 who underwent bone marrow transplantation. Cultures posi-
tive for fungus were identified from both the microbiology lab da-
tabase as well as medical record review to identify eighty-three
unique infections in fifty-four transplant patients. Results: The
overall incidence of fungal infections in BMT recipients was
16.7%. The predominant organisms included: Candida species
(55%) and Apergillus species (21%), with Candida albicans account-
ing for 19% of all fungal species. A variety of other fungal species
comprised the remainder of infections. The distribution of organ-
isms over time demonstrated a strong trend towards an increase
in rare molds in more recent years. The respiratory tract was the
main site of infection (41%) with urine (17%) and blood (11%)
also noted as significant sites. Upon stratification of the BMT pa-
tients who developed fungal infections, the primary diagnoses
were ALL (48%) and myeloid malignancy (35%); underlying diag-
nosis, however, had little impact on the development of a fungal in-
fection in BMT patients. Of all deaths in the studied population,
fungal-related mortality of patients analyzed was 44%. Conclu-
sions: Bone marrow transplant patients have a high risk of fungal
infections, likely secondary to their severe and prolonged neutrope-
nia. This risk appears to be increasing over time with rarer organ-
isms becoming more prevalent. This emphasizes the need for the
development and implementation of improved diagnostic and ther-
apeutic strategies in order to improve survival in this population.269
A PHASE II OPEN LABEL PILOT TRIAL OF EMPIRIC DAPTOMYCIN TREAT-
MENT FOR HEMATOLOGY-ONCOLOGY PATIENTS WITH FEBRILE NEU-
TROPENIA (FN)
Bubalo, J.S.1, Ciszewski, A.O.1, Kovascovics, T.J.1, Meyers, G.1,
Mauro, M.1, Epner, E.1, Jones, N.1, Hayes-Lattin, B.1,
Deninger, M.1, Curtin, P.T.2, Leis, J.F.2, Maziarz, R.T.1 1Oregon
Health and Sciences University Hospital, Portland, OR; 2University of
California San Diego, San Diego, CA; 3Mayo Clinic, Phoenix, AZ.
FN warrants prompt attention and treatment due to potential for
associated morbidity and mortality. Broad spectrum antibiotics are
guided by putative causative organisms. Initially gram-negative and
then gram positive organisms have emerged as infectious culprits.
Therefore vancomycin is often added in FN patients still febrile af-
ter 72 hours of initial antibiotic therapy. Emerging antibiotic resis-
tance by gram-positive organisms and the bacteriostatic nature of
vancomycin, make the study of new gram-positive therapies like
the novel bactericidal, antibiotic daptomycin, critical. This pilot
study aims to determine initial efficacy, safety, and pharmacokinet-
ics (PK), of daptomycin substituted for vancomycin in FN patients.
FN patients, without pneumonia, were enrolled and received dapto-
mycin per the current IDSA FN guidelines. Patients received 6 mg/
kg as a 30 minute intravenous infusion every 24 hours. Blood sam-
ples for measurement of plasma daptomycin concentrations were
collected for PK analysis. Twenty-eight patients, 19 men/9 women,
age range 24–74 years old (median 53) have been treated. Their
weights ranged from 56.2–137 kg (median of 89.9 kg). The patient’s
had the following malignancies: 10 AML, 6 ALL, 2 multiple mye-
loma, 2 Hodgkin’s disease, 2 non-Hodgkin’s lymphoma, 1 APL,
and 1 germ cell tumor. Ten patients were post autologous and 5
post allogeneic transplants, with 13 receiving non-transplant che-
motherapy. The median and mean time to reach an afebrile state
was 4 days. Mean duration receiving daptomycin was 11 days (me-
dian 8, range 3–40 days). Infectious organisms, identified for 16/28
patients, included: coagulase-negative S. aureus, alpha-hemolytic
streptococcus, S. mitis, S. oralis, P. aeruginosa, K. pneumonia, Co-
rynebacterium, and E. coli. One patient developed a drug rash
which abated after the cessation of daptomycin, and 1 experienced
mental status changes considered possibly related to taking dapto-
mycin. One patient stopped daptomycin secondary to parotitis for
which no organism was identified but improved when the patient
was changed to vancomycin. No patients experienced myositis or el-
evations in CK levels while on daptomycin. Daptomycin was safe
with no breakthrough gram positive infections and a mean time to
defervescence of 4 days. This pilot study supports future evaluation
100 Poster Session Iof the use of daptomycin in this setting. Compelte data, including
PK to be available for presentation.270
BK AND JC POLYOMAVIRUS VIREMIA IN ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANT PATIENTS: THERAPEUTIC ROLE OF FOSCARNET
Oholendt, M.S., Kamble, R.T., Carrum, G. Center for Cell and Gene
Therapy, Baylor College of Medicine and The Methodist Hospital, Hous-
ton, TX.
Background: The human polyomaviruses (JCV and BKV) are
ubiquitous. Infection acquired early in life remains latent in the
B-lymphocytes of immunocompetent hosts. The exact significance
of BKV and JCV reactivation following hematopoietic cell trans-
plant (HCT) is unknown but is increasingly being implicated in
hemorrhagic cystitis/nephritis (both BKV and JCV) as well as pro-
gressive multifocal leukoencephalopathy (JCV). Although cidofo-
vir, with accompanying nephrotoxicity, is increasingly used for
BKV-related hemorrhagic cystitis/nephritis, therapy for JCV is
not currently established. Methods: Incidental observation of de-
cline in the BKV and JCV viremia while receiving foscarnet
(FOS) for herpes infection (CMV, VZV, HHV-6) in 4 HCT pa-
tients form the basis of this report. Quantification of BKV and
JCV viremia was obtained using polymerase chain reaction
(qPCR). Testing was repeated weekly or as indicated during the
course of FOS. Results: Four patients with eleven initial or reacti-
vation FOS-treatment episodes were recorded. The median age of 3
males and 1 female was 43.5 years (range 19–60). BKV/JCV reacti-
vation occurred at a median of 73.5 days (range 33–398) which was
asymptomatic in 3 patients; one patient had grade II hemorrhagic
cystitis. FOS incidentally resulted in marked reduction in BKV
and JCV viremia; the median time to $ 50% reduction in viremia
was 8 days for both BKV and JCV. The best response for BKV
and JCV was a median reduction of 89% (range 27–100) and 63%
(range 26–98) in DNA copies respectively. Conclusions: Given
the high incidence of nephrotoxicty with cidofovir, our observation
warrants further assessment of FOS for the treatment of BKV and
JCV infections in the allogeneic HCT patient.271
RECOMBINANT FACTOR 7A IN PAEDIATRIC STEM CELL TRANSPLANT
SUPPORTIVE CARE
Jessop, M.E., Lockwood, L.R., Hallahan, A., Smith, E.K., Little, M.A.
Royal Childrens Hospital, Brisbane, Queensland, Australia.
Recombinant factor7a (r7a) is structurally almost identical to
plasma derived VIIa and promotes haemostasis by activating factors
IX and X when complexed to tissue factor. There is established use
of r7a in trauma, surgical and obstetric bleeding, patients with ac-
quired haemophilia, and in the management of haemophilia pa-
tients with inhibitors to factor VIII or IX. Increasing use of this
drug has developed in haematology/oncology practice with varied
outcomes. An audit of the use of r7a in the Stem Cell Transplant
Unit at Royal Children’s Hospital Brisbane was conducted.
Ten treatment episodes in six patients were identified (one pa-
tient pre stem cell collection, four patients immediately post
BMT and one patient 12 mths post BMT). In the patient who de-
veloped intrathoracic bleeding post vascath insertion for stem cell
collection, the bleeding responded to r7a in combination with other
haemostatic agents with complete recovery. The four patients in the
immediate post BMT period were managed during five bleeding ep-
isodes with a wide range of doses of r7a. Indications for r7a in these
patients were bleeding due to: GVHD (3), mucositis (1), pulmonary
haemorrhage (1). Three of these patients had GVHD with two of
the three patients achieving a partial response to treatment and
one without response. All three of these patients died with active
bleeding. The fourth patient had two bleeding episodes (life threat-
ening mucosal and pulmonary haemorrhage) and responded to
treatment during both episodes.One patient developed refractory immune mediated thrombocy-
topenia 12 months post allogeneic BMT for ALL. He received r7a
during 4 separate treatment episodes (gastrointestinal bleeding,
subdural haemorrhage, mucosal and gastrointestinal bleeding, dur-
ing splenectomy). Bleeding was controlled on all four occasions.
All patients with refractory GVHD and gastrointestinal bleeding
failed to have sustained responses and the outcomes in this group
were universally poor. In those patients with reversible underlying
pathology r7a was useful in sustaining haemostatic control with
a good overall survival. r7a is an exciting addition to our haemostatic
agents but the varied outcomes and high cost of this drug indicate
that further study and development of guidelines for use in stem
cell transplant is warranted.272
CYTOMEGALOVIRUS (CMV) SPECIFIC CYTOTOXIC T LYMPHOCYTES
FROM A CMV SERO-NEGATIVE DONOR FOR PERSISTENT CMV INFEC-
TION POST-TRANSPLANT
Lucas, K.1, Cowan, M.2, Horn, B.2, Dunham, K.1, Bao, L.1 1Penn State
Children’s Hospital, Hershey, PA; 2UCSF Children’s Hospital, San
Francisco, CA.
Cytomegalovirus (CMV) reactivation following an allogeneic
stem cell transplant (SCT) can be a challenging clinical situation
when the stem cell donor is serologically negative for CMV or the
graft has been T cell depleted. We present a patient with myelodys-
plastic syndrome who received a T cell depleted, haplo-identical
SCT from his CMV sero-negative father and developed persistent
CMV infection, uveitis, and encephalitis, despite several months
of anti-viral agents, including ganciclovir, foscarnet, and cidofovir.
He had improvement in his encephalitis but had persistent CMV vi-
remia despite these agents. His CMV sero-negative father received
a single vaccination with the Towne strain of CMV (from Dr. Stuart
Adler, Medical College of Virginia), and 10 days later CMV specific
cytotoxic T lymphocytes (CTL) were expanded using a pool of
15-mer CMV pp65 overlapping peptides. CMV pp65 CTL were stim-
ulated once with peptide pulsed monocytes, had pp65 specific cyto-
toxicity, and lacked auto- or allo-reactivity by chromium release
assay. All antivirals were discontinued two weeks prior to his
CTL infusion due to pancytopenia, which was thought to be due
to prolonged use of cidofovir. He received a single dose of 2 
105 CMV CTL pp65/kg. CMV viral load decreased from 1900 cop-
ies/ml pre-infusion to 100 copies/ml three weeks post-infusion,
which was followed by three consecutive weeks with no detectable
CMV by PCR. All clinical signs of CMV infection have resolved,
without the use of anti-CMV medications. CMV pp65 specific cy-
totoxicity was in the normal range by 4 weeks post-infusion. Unfor-
tunately our patient was diagnosed with recurrent leukemia at 3
weeks post-infusion, precluding long-term follow-up of his immune
status. Considering the fact that this patient did not receive any
other intervention for his CMV infection during this time period,
it seems possible that his clinical, immunologic and virologic im-
provement could have occurred as a result of the CMV CTL infu-
sion. The vaccination was well tolerated by the donor, and the
culture method was relatively simple, making this a strategy that
can be applied in similar situations.273
AIR FILTRATION IN STEM CELL TRANSPLANT UNITS: IS IT ALWAYS NEC-
ESSARY?
Wood, C.E., Johnson, L.R., Carter, J.M., Anthony, B. Wellington Hos-
pital, Wellington, New Zealand.
Infections are a significant cause of morbidity and mortality in re-
cipients of allogeneic haematopoietic stem cell transplants. Interna-
tional guidelines exist regarding prevention and treatment of
bacterial, viral and fungal infections in this setting. The use of
HEPA filtered air is often mandated by best practise guidelines to
reduce infection, especially Aspergillus and other spore born fungi.
The evidence basis for this is debatable and implementation of these
